Development of a Native Fractionation Antigen Microarray for Autoantibody Profiling in Breast Cancer
Final rept. 15 Sep 2009-14 Sep 2011
BRIGHAM AND WOMENS HOSPITAL BOSTON MA
Pagination or Media Count:
The humoral response of a cancer patient may allow earlier detection of cancer than current methods allow. If so, the serum autoantibody repertoire from cancer patients might be exploited for autoantibody profiling, and aid in the serological diagnosis of cancer. In this final report, we report on the development of a whole proteome native antigen microarray for human breast cancer. Using this platform and sera from stage 1 and 2 invasive ductal carcinoma of the breast as well as normal controls, we identified antigen containing fractions that were significantly differentially reactive with the cancer sera p less than or equal to 0.05. Receiver operator characteristics curves were plotted for the top 5 reactive fractions and the area under the curve AUC was calculated. Our findings showed that when combined, the 5 reactive fractions have an AUC of 0.89 for stage 1 breast cancers versus normal controls, and an AUC of 0.82 for stage 2 breast cancers versus normal controls. Our results suggest that our platform can identify specific immune response signatures that might serve as biomarkers.
- Medicine and Medical Research